Screener
Discontinued — last reported Q3 '24
CapEx at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Palvella Therapeutics’s 10-Q, filed November 13, 2024.
- Filed
- Nov 13, 2024
- Fiscal quarter
- Q3 FY2024
- Calendar quarter
- Q3 2024
- Accession
- 0001437749-24-034891
- Nine Months Ended September 30,
- 2024 2023
- Operating activities:
- Net loss $ (11,369 ) $ (19,959 )
- Adjustments to reconcile net loss to net cash used in operating activities:
- Depreciation and amortization (accretion) (30 ) 2,102
- Right-of-use asset accretion — (98 )
- Stock-based compensation 1,223 2,898
- Gain on sale of fixed assets (225 )
- Asset impairment — 14,893
- Prepaid rent 1,118 —
- Realized investment losses — (53 )
- Other non-cash transactions 864 (129 )
- Changes in operating assets and liabilities 89 (33,804 )
- Net cash used in operating activities (8,330 ) (34,150 )
- Investing activities:
- Purchases of property and equipment — (184 )
- Proceeds from maturity of investments 9,000 24,007
- Proceeds on sale of fixed assets 2,318 —
- Purchases of investments — (15,270 )
- Net cash provided by investing activities 11,318 8,553
- Financing activities:
- Proceeds from employee stock purchase plan — 52
- Proceeds from issuance of common stock resulting from ATM sales, net of $0.7 million in transaction costs — 19,729
- Net cash provided by financing activities — 19,781
- Effect of exchange rate change on cash and cash equivalents (1,021 ) 75
- Net increase in cash and cash equivalents 1,967 (5,741 )
- Cash and cash equivalents at beginning of period 17,396 38,635
- Cash and cash equivalents at end of period $ 19,363 $ 32,894
- Supplemental cash flow disclosures:
- Net unrealized gain (loss) on investments $ (1 ) $ 74
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's capex?
- Palvella Therapeutics (PVLA) reported capex of $0 in Q3 2024.
- How has Palvella Therapeutics's capex changed year-over-year?
- Palvella Therapeutics's capex decreased by 100.0% year-over-year, from $69K to $0.
- What is the long-term trend for Palvella Therapeutics's capex?
- Over 2 years (2021 to 2023), Palvella Therapeutics's capex has grown at a -56.0% compound annual growth rate (CAGR), from $949K to $184K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Palvella Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude